In vivo studies demonstrated that down-regulation of USP8 inhibited HER-3 positive tumors growth. Down-regulation of USP8 inhibits HER-3 positive GC cells proliferation in vivo and in vitro, which indicate that USP8 represents a feasible choice as a therapeutic target for HER-3 positive GC cells.